Bauer Eugene 4
4 · Evommune, Inc. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
Bauer Eugene
DirectorChief Medical Officer
Transactions
- Conversion
Series Seed Preferred Stock
2025-11-07−206,355→ 0 total→ Common Stock (24,225 underlying) - Conversion
Series B Preferred Stock
2025-11-07−12,500→ 0 total→ Common Stock (1,587 underlying) - Conversion
Common Stock
2025-11-07+25,812→ 272,296 total
Footnotes (2)
- [F1]Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
- [F2]Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.